Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling; Guidance for Industry and Food and Drug Administration Staff; Availability, 13864-13865 [2015-06029]
Download as PDF
mstockstill on DSK4VPTVN1PROD with NOTICES
13864
Federal Register / Vol. 80, No. 51 / Tuesday, March 17, 2015 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; AIDS and
AIDS Related Research.
Date: March 18, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Jose H Guerrier, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1137, guerriej@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Respiratory Sciences Special Panel.
Date: March 19–20, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Lawrence E Boerboom,
Ph.D., Chief, CVRS IRG, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 4130, MSC 7814,
Bethesda, MD 20892, (301) 435–8367,
boerboom@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory Sciences Special Panel.
Date: March 24–25, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Lawrence E Boerboom,
Ph.D., Chief, CVRS IRG, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 4130, MSC 7814,
Bethesda, MD 20892, (301) 435–8367,
boerboom@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 11, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–06036 Filed 3–16–15; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:09 Mar 16, 2015
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–D–0293]
Reprocessing Medical Devices in
Health Care Settings: Validation
Methods and Labeling; Guidance for
Industry and Food and Drug
Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of the guidance entitled
‘‘Reprocessing Medical Devices in
Health Care Settings: Validation
Methods and Labeling.’’ This guidance
provides recommendations for the
formulation and scientific validation of
reprocessing instructions for reusable
medical devices. This guidance
document also provides
recommendations for the content and
review procedures for premarket
notification (510(k)) submissions,
premarket approval (PMA) applications,
humanitarian device exemption (HDE)
applications, de novo requests, and
investigational device exemption (IDE)
applications, concerning the labeling
instructions for reprocessing reusable
medical devices. This guidance reflects
the scientific advances in knowledge
and technology involved in reprocessing
reusable medical devices, especially
more complex, reusable medical device
designs that are more difficult to
reprocess.
SUMMARY:
Submit either electronic or
written comments on this guidance at
any time. General comments on Agency
guidance documents are welcome at any
time.
ADDRESSES: An electronic copy of the
guidance document is available for
download from the Internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Reprocessing
Medical Devices in Health Care Settings:
Validation Methods and Labeling’’ to
the Office of the Center Director,
Guidance and Policy Development,
Center for Devices and Radiological
Health, Food and Drug Administration,
10903 New Hampshire Ave. Bldg. 66,
Rm. 5431, Silver Spring, MD 20993–
0002; or the Office of Communication,
Outreach and Development, Center for
Biologics Evaluation and Research
(CBER), Food and Drug Administration,
DATES:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
10903 New Hampshire Ave. Bldg. 71,
Rm. 3128, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your request.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Angela C. Krueger, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1666, Silver Spring,
MD 20993–0002, 301–796–6380; or
Stephen Ripley, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave. Bldg. 71, Rm. 7301,
Silver Spring, MD 20993, 240–402–
7911.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, there has been a
significant advance in knowledge and
technology involved in reprocessing
reusable medical devices. Additionally,
there has been an evolution towards
more complex medical device designs
that are more difficult to clean,
disinfect, and sterilize. This guidance
reflects the scientific advances in these
areas. Under section 502(f) of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 352(f)), a device must have
adequate directions for use, which
include instructions on preparing a
device for use. Instructions on how to
reprocess (i.e., clean, disinfect, and
sterilize) a reusable device are critical to
ensure that the device is appropriately
prepared for its next use.
In the Federal Register of May 2, 2011
(76 FR 24494), FDA announced the
availability of the draft guidance.
Interested persons were invited to
comment by August 1, 2011. FDA
reviewed and considered all the public
comments we received and revised
several sections of the guidance, where
applicable. On June 8 and 9, 2011, FDA
held a public workshop entitled
‘‘Reprocessing of Reusable Medical
Devices Workshop.’’ The purpose of the
workshop was to discuss factors
affecting the reprocessing of reusable
medical devices and FDA’s plans to
address the identified issues. The
discussion during this workshop and
the comments received were considered
before revising the guidance. This final
guidance supersedes ‘‘Labeling Reusable
E:\FR\FM\17MRN1.SGM
17MRN1
Federal Register / Vol. 80, No. 51 / Tuesday, March 17, 2015 / Notices
Medical Devices for Reprocessing in
Health Care Facilities: FDA Reviewer
Guidance’’ dated April 1996.
This final guidance contains the
addition of ‘‘Appendix E: Devices for
which a 510(k) Should Contain Data to
Validate Reprocessing Instructions,’’
which includes a subset of medical
devices that FDA has identified that
pose a greater likelihood of microbial
transmission and represent a high risk
of infection if they are not adequately
reprocessed. Because of this greater
public health risk, 510(k) submissions
for these devices should include
protocols and complete test reports of
the validation of the reprocessing
instructions so that FDA has the
information it needs to evaluate
substantial equivalence.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the Agency’s
current thinking on reprocessing
validation methods and labeling for
medical devices. It does not create or
confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statute
and regulations.
mstockstill on DSK4VPTVN1PROD with NOTICES
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by using the
Internet. A search capability for all
CDRH guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.fda.gov/BiologicsBlood
Vaccines/GuidanceCompliance
RegulatoryInformation/Guidances/
default.htm or https://
www.regulations.gov. Persons unable to
download an electronic copy of
‘‘Reprocessing Medical Devices in
Health Care Settings: Validation
Methods and Labeling’’ may send an
email request to CDRHGuidance@fda.hhs.gov to receive an
electronic copy of the document. Please
use the document number 1748 to
identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
VerDate Sep<11>2014
18:09 Mar 16, 2015
Jkt 235001
3520). The collections of information in
21 CFR parts 801 and 809 have been
approved under OMB control number
0910–0485 (medical device labeling);
the collections of information in 21 CFR
part 807, subpart E have been approved
under OMB control number 0910–0120
(premarket notification); the collections
of information in 21 CFR part 812 have
been approved under OMB control
number 0910–0078 (investigational
device exemption); the collections of
information in 21 CFR part 814,
subparts A through E have been
approved under OMB control number
0910–0231 (premarket approval); the
collections of information in 21 CFR
part 814, subpart H have been approved
under OMB control number 0910–0332
(humanitarian use devices); and the
collections of information in 21 CFR
part 820 have been approved under
OMB control number 0910–0073
(quality system regulation).
V. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: March 11, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–06029 Filed 3–16–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request Surveys To Support an
Evaluation of the National Human
Genome Research Institute (NHGRI)
Summer Workshop in Genomics (Short
Course)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Human Genome Research
Institute (NHGRI), National Institutes of
Health (NIH), will publish periodic
summaries of proposed projects to be
submitted to the Office of Management
SUMMARY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
13865
and Budget (OMB) for review and
approval.
Written comments and/or suggestions
from the public and affected agencies
are invited on one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
To Submit Comments And For
Further Information: To obtain a copy of
the data collection plans and
instruments, submit comments in
writing, or request more information on
the proposed project, contact: Carla L.
Easter, Ph.D., Chief, Education and
Community Involvement Branch,
NHGRI, Building 31, Room B1B55, 31
Center Drive, MSC 2070, Bethesda, MD
20892 or call non-toll-free number (301)
594–1364 or Email your request,
including your address to: easterc@
mail.nih.gov. Formal requests for
additional plans and instruments must
be requested in writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: Surveys to
Support an Evaluation of the NHGRI
Summer Workshop in Genomics (Short
Course), 0925–NEW, National Human
Genome Research Institute (NHGRI),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The purpose of the proposed
data collection activity is to complete a
full-scale outcome evaluation of
NHGRI’s Summer Workshop in
Genomics (a.k.a., the ‘‘Short Course’’)
focusing on program participants
between 2004 and 2012. This training
program is an intensive multi-day
course that updates instructors and
researchers of biology and nursing (and
other related disciplines) on the latest
research trends and topics in genomic
science. The course focuses on the
continuing effort to find the genetic
basis of various diseases and disorders,
and current topics on the ethical, legal
and social implications of genomics.
E:\FR\FM\17MRN1.SGM
17MRN1
Agencies
[Federal Register Volume 80, Number 51 (Tuesday, March 17, 2015)]
[Notices]
[Pages 13864-13865]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06029]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-D-0293]
Reprocessing Medical Devices in Health Care Settings: Validation
Methods and Labeling; Guidance for Industry and Food and Drug
Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the guidance entitled ``Reprocessing Medical Devices in
Health Care Settings: Validation Methods and Labeling.'' This guidance
provides recommendations for the formulation and scientific validation
of reprocessing instructions for reusable medical devices. This
guidance document also provides recommendations for the content and
review procedures for premarket notification (510(k)) submissions,
premarket approval (PMA) applications, humanitarian device exemption
(HDE) applications, de novo requests, and investigational device
exemption (IDE) applications, concerning the labeling instructions for
reprocessing reusable medical devices. This guidance reflects the
scientific advances in knowledge and technology involved in
reprocessing reusable medical devices, especially more complex,
reusable medical device designs that are more difficult to reprocess.
DATES: Submit either electronic or written comments on this guidance at
any time. General comments on Agency guidance documents are welcome at
any time.
ADDRESSES: An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Reprocessing Medical Devices in Health Care Settings: Validation
Methods and Labeling'' to the Office of the Center Director, Guidance
and Policy Development, Center for Devices and Radiological Health,
Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 66, Rm.
5431, Silver Spring, MD 20993-0002; or the Office of Communication,
Outreach and Development, Center for Biologics Evaluation and Research
(CBER), Food and Drug Administration, 10903 New Hampshire Ave. Bldg.
71, Rm. 3128, Silver Spring, MD 20993-0002. Send one self-addressed
adhesive label to assist that office in processing your request.
Submit electronic comments on the guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Angela C. Krueger, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 1666, Silver Spring, MD 20993-0002, 301-
796-6380; or Stephen Ripley, Center for Biologics Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave. Bldg.
71, Rm. 7301, Silver Spring, MD 20993, 240-402-7911.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, there has been a significant advance in knowledge
and technology involved in reprocessing reusable medical devices.
Additionally, there has been an evolution towards more complex medical
device designs that are more difficult to clean, disinfect, and
sterilize. This guidance reflects the scientific advances in these
areas. Under section 502(f) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 352(f)), a device must have adequate directions for use,
which include instructions on preparing a device for use. Instructions
on how to reprocess (i.e., clean, disinfect, and sterilize) a reusable
device are critical to ensure that the device is appropriately prepared
for its next use.
In the Federal Register of May 2, 2011 (76 FR 24494), FDA announced
the availability of the draft guidance. Interested persons were invited
to comment by August 1, 2011. FDA reviewed and considered all the
public comments we received and revised several sections of the
guidance, where applicable. On June 8 and 9, 2011, FDA held a public
workshop entitled ``Reprocessing of Reusable Medical Devices
Workshop.'' The purpose of the workshop was to discuss factors
affecting the reprocessing of reusable medical devices and FDA's plans
to address the identified issues. The discussion during this workshop
and the comments received were considered before revising the guidance.
This final guidance supersedes ``Labeling Reusable
[[Page 13865]]
Medical Devices for Reprocessing in Health Care Facilities: FDA
Reviewer Guidance'' dated April 1996.
This final guidance contains the addition of ``Appendix E: Devices
for which a 510(k) Should Contain Data to Validate Reprocessing
Instructions,'' which includes a subset of medical devices that FDA has
identified that pose a greater likelihood of microbial transmission and
represent a high risk of infection if they are not adequately
reprocessed. Because of this greater public health risk, 510(k)
submissions for these devices should include protocols and complete
test reports of the validation of the reprocessing instructions so that
FDA has the information it needs to evaluate substantial equivalence.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
Agency's current thinking on reprocessing validation methods and
labeling for medical devices. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of the applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
using the Internet. A search capability for all CDRH guidance documents
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or https://www.regulations.gov. Persons unable to
download an electronic copy of ``Reprocessing Medical Devices in Health
Care Settings: Validation Methods and Labeling'' may send an email
request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of
the document. Please use the document number 1748 to identify the
guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR parts 801 and 809 have been
approved under OMB control number 0910-0485 (medical device labeling);
the collections of information in 21 CFR part 807, subpart E have been
approved under OMB control number 0910-0120 (premarket notification);
the collections of information in 21 CFR part 812 have been approved
under OMB control number 0910-0078 (investigational device exemption);
the collections of information in 21 CFR part 814, subparts A through E
have been approved under OMB control number 0910-0231 (premarket
approval); the collections of information in 21 CFR part 814, subpart H
have been approved under OMB control number 0910-0332 (humanitarian use
devices); and the collections of information in 21 CFR part 820 have
been approved under OMB control number 0910-0073 (quality system
regulation).
V. Comments
Interested persons may submit either electronic comments regarding
this document to https://www.regulations.gov or written comments to the
Division of Dockets Management (see ADDRESSES). It is only necessary to
send one set of comments. Identify comments with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday, and will be posted to the docket at https://www.regulations.gov.
Dated: March 11, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-06029 Filed 3-16-15; 8:45 am]
BILLING CODE 4164-01-P